Physician profile
Mark H Biscow
NPI 1871510354
$972.32
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.93 · 2020: $48.09 · 2021: $476 · 2022: $119 · 2023: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $191.71 | 2021-2023 | Otezla, Repatha, Evenity |
| Idorsia Pharmaceuticals US INC | $142.47 | 2023 | Quviviq |
| Abbvie INC. | $78.70 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $60.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $50.21 | 2021 | |
| Novo Nordisk INC | $49.94 | 2020-2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $49.11 | 2022 | |
| Bausch Health US, LLC | $48.38 | 2021-2022 | |
| Ibsa Pharma INC. | $40.87 | 2020-2021 | |
| Clarus Therapeutics INC. | $39.31 | 2021 | |
| Lilly USA, LLC | $37.24 | 2021-2023 | Mounjaro |
| Pfizer INC. | $37.23 | 2019-2021 | |
| Boston Scientific Corporation | $30.20 | 2021 | |
| Almatica Pharma LLC | $29.56 | 2021 | |
| Endo Pharmaceuticals INC. | $23.60 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $22.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.87 | 2021 | |
| Allergan, INC. | $13.34 | 2020 | |
| Eisai INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Biscow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.